Dr. Tae Kon Kim

Dr. Tae Kon Kim is a physician-scientist at Vanderbilt University Medical Center specializing in acute myeloid leukemia (AML) research. His work focuses on understanding immune evasion mechanisms in AML, particularly through the study of PD-1H/VISTA signaling pathways. Dr. Kim's research has demonstrated that programmed death-1 homolog (PD-1H) is highly expressed in AML blasts and plays a critical role in evading T cell-mediated immune responses. His groundbreaking work has shown that ablation of PD-1H can significantly inhibit AML progression and that combination therapy with anti-PD therapy confers synergistic antileukemia effects.